stockrowBioNTech SE Sponsored ADR
BNTX Healthcare Biotechnology
BioNTech SE Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 9.07% from fiscal 2024.
- Revenue
- −16.4%
- EPS
- +708.4%
- Free cash flow
- −123.8%
- Total debt
- +44.4%
Quarter to September 2026, against a year earlier
Follow BNTX
Alert me
BioNTech SE Sponsored ADR (BNTX) Revenue
BioNTech SE Sponsored ADR's revenue for fiscal 2025 was $3.2B, up 9.07% from $3.0B in fiscal 2024. Over the twelve months to 30 September 2026 it was $2.7B. Over the past ten years it has ranged from $69.0M (fiscal 2017) to $22.5B (fiscal 2021); the current reading is higher than 67% of that period. BioNTech SE Sponsored ADR ranks 10th of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $3.2B | 9.07% |
| FY2024 | $3.0B | (27.98%) |
| FY2023 | $4.1B | (77.34%) |
| FY2022 | $18.2B | (18.76%) |
| FY2021 | $22.5B | 3,974.95% |
| FY2020 | $551.0M | 353.02% |
| FY2019 | $121.6M | (19.28%) |
| FY2018 | $150.7M | 118.36% |
| FY2017 | $69.0M | — |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $1.5B | 1,108.55% |
| Jun 2026 | $122.8M | (11.17%) |
| Mar 2026 | $138.2M | (85.94%) |
| Dec 2025 | $982.9M | (44.64%) |
| 24 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| INCY Incyte Corporation compare | $6.0B |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $5.0B |
| GMAB Genmab A/S Sponsored ADR compare | $4.1B |
| BNTX BioNTech SE Sponsored ADR | $2.7B |
| EXEL Exelixis, Inc. compare | $2.5B |
| INSM Insmed, Inc. compare | $1.5B |
| ASND Ascendis Pharma A/S compare | $1.2B |
| BBIO BridgeBio Pharma, Inc. compare | $945.5M |
| ROIV Roivant Sciences Ltd. compare | $7.5M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on BNTX
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Beneish M-score
- The full statement